Sunshine Biopharma Inc. (SBFMW) stock
SBFMWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SBFM
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 10/30
$0.03+0.00 (+2.00%)
Close on Oct 30, 2026Market cap $11.36MP/E –Yield –
Sunshine Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Sunshine Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $237.75K, down 65.4% year over year. For fiscal 2025 it was $604.31K, down 35.3% from the year before. Over ten years it grew 52.9% a year on average. The highest annual figure on record is $1.86M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $604.31K | -35.3% |
| FY2024 | Dec 31, 2024 | $933.90K | -49.7% |
| FY2023 | Dec 31, 2023 | $1.86M | +128.6% |
| FY2022 | Dec 31, 2022 | $811.86K | +20.8% |
| FY2021 | Dec 31, 2021 | $672.21K | +38801.0% |
| FY2020 | Dec 31, 2020 | $1.73K | -88.6% |
| FY2019 | Dec 31, 2019 | $15.20K | +18.8% |
| FY2018 | Dec 31, 2018 | $12.80K | – |
| FY2017 | Dec 31, 2017 | $0 | -100.0% |
| FY2016 | Dec 31, 2016 | $32.79K | +278.8% |
| FY2015 | Dec 31, 2015 | $8.66K | -97.4% |
| FY2014 | Dec 31, 2014 | $327.00K | +138.0% |
| FY2013 | Dec 31, 2013 | $137.40K | +7412.3% |
| FY2012 | Dec 31, 2012 | $1.83K | -98.7% |
| FY2011 | Dec 31, 2011 | $142.65K | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $13.22K | -93.3% |
| Q1 FY2026 | Mar 31, 2026 | $31.72K | -85.3% |
| Q4 FY2025 | Dec 31, 2025 | $73.50K | -50.8% |
| Q3 FY2025 | Sep 30, 2025 | $119.30K | -5.6% |
| Q2 FY2025 | Jun 30, 2025 | $196.23K | -55.0% |
| Q1 FY2025 | Mar 31, 2025 | $215.28K | -3.0% |
| Q4 FY2024 | Dec 31, 2024 | $149.27K | -81.7% |
| Q3 FY2024 | Sep 30, 2024 | $126.36K | -46.9% |
| Q2 FY2024 | Jun 30, 2024 | $436.24K | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | $222.03K | -48.7% |
| Q4 FY2023 | Dec 31, 2023 | $816.33K | +1854.7% |
| Q3 FY2023 | Sep 30, 2023 | $238.01K | -34.3% |
| Q2 FY2023 | Jun 30, 2023 | $368.57K | +702.2% |
| Q1 FY2023 | Mar 31, 2023 | $432.93K | +19.7% |
| Q4 FY2022 | Dec 31, 2022 | $41.76K | -54.2% |
| Q3 FY2022 | Sep 30, 2022 | $362.50K | +62.9% |
| Q2 FY2022 | Jun 30, 2022 | $45.94K | -76.0% |
| Q1 FY2022 | Mar 31, 2022 | $361.65K | +116.8% |
| Q4 FY2021 | Dec 31, 2021 | $91.20K | +5177.7% |
| Q3 FY2021 | Sep 30, 2021 | $222.47K | – |
| Q2 FY2021 | Jun 30, 2021 | $191.76K | – |
| Q1 FY2021 | Mar 31, 2021 | $166.79K | – |
| Q4 FY2020 | Dec 31, 2020 | $1.73K | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | -100.0% |
| Q2 FY2020 | Jun 30, 2020 | $0 | – |
| Q1 FY2020 | Mar 31, 2020 | $0 | -100.0% |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $15.20K | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $12.80K | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q4 FY2016 | Dec 31, 2016 | $0 | – |
| Q3 FY2016 | Sep 30, 2016 | $0 | – |